Celagenex Research (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 07-12-2024
- Paid Up Capital ₹ 0.18 M
as on 07-12-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 1818.39%
(FY 2021)
- Profit -203.81%
(FY 2021)
- Ebitda -128.62%
(FY 2021)
- Net Worth 494.13%
(FY 2021)
- Total Assets 671.57%
(FY 2021)
About Celagenex Research (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.18 M, as per Ministry of Corporate Affairs (MCA) records.
Rajaram Samant and Dilip Nevrekar serve as directors at the Company.
- CIN/LLPIN
U36997MH2019PTC331430
- Company No.
331430
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Oct 2019
- Date of AGM
14 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Celagenex Research (India) Private Limited offer?
Celagenex Research (India) Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Extracts, Fruit Extracts, Nutraceuticals & Dietary Supplements, Dietary Supplements, Pharma Ingredients & Raw Materials, Vitamin Powder API, Nutraceuticals, Pharmaceutical Excipients.
Who are the key members and board of directors at Celagenex Research (India)?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajaram Samant  | Director | 25-Mar-2020 | Current |
| Dilip Nevrekar | Director | 01-Sep-2022 | Current |
Financial Performance and Corporate Structure Insights of Celagenex Research (India).
Celagenex Research (India) Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 1818.39% increase. The company also saw a substantial fall in profitability, with a 203.81% decrease in profit. The company's net worth Soared by an impressive increase of 494.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Celagenex Research (India)?
In 2021, Celagenex Research (India) had a public holding of 2.51%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Celagenex Research (India)?
Celagenex Research (India) has a workforce of 390 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Celagenex Research (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Celagenex Research (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
